KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) Return on Capital Employed: 2021-2023

Historic Return on Capital Employed for AbCellera Biologics (ABCL) over the last 3 years, with Dec 2023 value amounting to -0.17%.

  • AbCellera Biologics' Return on Capital Employed fell 32.00% to -0.17% in Q4 2023 from the same period last year, while for Dec 2023 it was -0.17%, marking a year-over-year decrease of 32.00%. This contributed to the annual value of -0.23% for FY2024, which is 6.00% down from last year.
  • Latest data reveals that AbCellera Biologics reported Return on Capital Employed of -0.17% as of Q4 2023, which was down 16.27% from -0.15% recorded in Q3 2023.
  • AbCellera Biologics' Return on Capital Employed's 5-year high stood at 0.32% during Q1 2021, with a 5-year trough of -0.17% in Q4 2023.
  • Its 3-year average for Return on Capital Employed is 0.12%, with a median of 0.19% in 2021.
  • Data for AbCellera Biologics' Return on Capital Employed shows a maximum YoY slumped of 38bps (in 2023) over the last 5 years.
  • AbCellera Biologics' Return on Capital Employed (Quarterly) stood at 0.18% in 2021, then decreased by 3bps to 0.15% in 2022, then tumbled by 32bps to -0.17% in 2023.
  • Its last three reported values are -0.17% in Q4 2023, -0.15% for Q3 2023, and -0.08% during Q2 2023.